STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding
In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.
Zepbound (tirzepatide), the Most Prescribed Weight Management Medication in 2025, Now Available in Multi-Dose KwikPen
INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use…
Novo’s next-gen obesity drug fails to beat Lilly’s Zepbound
Shares in Novo Nordisk A/S took another battering after the company announced its next-generation obesity drug Cagrisema failed to show noninferiority to Eli Lilly and Co. Inc.’s Zepbound in an open-label comparator study.
Semaglutide May Increase Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
MONDAY, Feb. 23, 2026 — People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 inhibitors (SGLT2is), according…
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and the bet did not pay off.
Results Outweigh Side Effects Among Ozempic/Wegovy Users, Study Says
MONDAY, Feb. 23, 2026 — Side effects like nausea or vomiting are common among folks taking Ozempic/Wegovy, but they’ll grin and bear it if they think they’re losing weight, a new study finds.The drugs’ perceived effectiveness — lost weight, less app…
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday.
Patients in the REDEFINE 4 …
What to Know About Trying to Conceive If You’re Taking a GLP-1
Medications for obesity may improve fertility, but there are many unknowns when it comes to using them during pregnancy.
Study finds tirzepatide cuts alcohol intake by more than half in rodents
For the first time, researchers show that tirzepatide—the active ingredient in the diabetes and weight-loss drug Mounjaro—reduces alcohol intake as well as relapse-like behaviors in rats and mice. The findings are considered relevant in the search for new treatments for alcohol use disorder. Researchers at the University of Gothenburg have previously demonstrated that semaglutide, found in the diabetes and weight-loss drugs Ozempic and Wegovy, reduces alcohol consumption in rats. In the current study, published in the journal eBioMedicine, the focus shifts to tirzepatide and Mounjaro.
Midsize Bodies Were Finally Going Mainstream—Then GLP-1s Came Along
Could weight-loss drugs shrink the body representation we’ve spent decades seeking?